BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

177 related articles for article (PubMed ID: 36996377)

  • 21. Genomic alterations predictive of poor clinical outcomes in pan-cancer.
    Seldon CS; Meiyappan K; Hoffman H; Guo JA; Goel N; Hwang WL; Nguyen PL; Mahal BA; Alshalalfa M
    Oncotarget; 2022; 13():1069-1077. PubMed ID: 36187555
    [TBL] [Abstract][Full Text] [Related]  

  • 22. RUNX2 (6p21.1) amplification in osteosarcoma.
    Gupta S; Ito T; Alex D; Vanderbilt CM; Chang JC; Islamdoust N; Zhang Y; Nafa K; Healey J; Ladanyi M; Hameed MR
    Hum Pathol; 2019 Dec; 94():23-28. PubMed ID: 31669178
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Clinical impact of the methotrexate resistance-associated genes C-MYC and dihydrofolate reductase (DHFR) in high-grade osteosarcoma.
    Scionti I; Michelacci F; Pasello M; Hattinger CM; Alberghini M; Manara MC; Bacci G; Ferrari S; Scotlandi K; Picci P; Serra M
    Ann Oncol; 2008 Aug; 19(8):1500-1508. PubMed ID: 18385200
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Molecular analysis of p53, MDM2, and H-ras genes in osteosarcoma and malignant fibrous histiocytoma of bone in patients older than 40 years.
    Kawaguchi K; Oda Y; Sakamoto A; Saito T; Tamiya S; Iwamoto Y; Tsuneyoshi M
    Mod Pathol; 2002 Aug; 15(8):878-88. PubMed ID: 12181274
    [TBL] [Abstract][Full Text] [Related]  

  • 25. How Are Indeterminate Pulmonary Nodules at Diagnosis Associated with Survival in Patients with High-Grade Osteosarcoma?
    Tsoi KM; Lowe M; Tsuda Y; Lex JR; Fujiwara T; Almeer G; Gregory J; Stevenson J; Evans SE; Botchu R; Jeys LM
    Clin Orthop Relat Res; 2021 Feb; 479(2):298-308. PubMed ID: 32956141
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Characterization of the 12q15 MDM2 and 12q13-14 CDK4 amplicons and clinical correlations in osteosarcoma.
    Mejia-Guerrero S; Quejada M; Gokgoz N; Gill M; Parkes RK; Wunder JS; Andrulis IL
    Genes Chromosomes Cancer; 2010 Jun; 49(6):518-25. PubMed ID: 20196171
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Coamplification of Myc/Pvt1 and homozygous deletion of Nlrp1 locus are frequent genetics changes in mouse osteosarcoma.
    Rao PH; Zhao S; Zhao YJ; Yu A; Rainusso N; Trucco M; Allen-Rhoades W; Satterfield L; Fuja D; Borra VJ; Man TK; Donehower LA; Yustein JT
    Genes Chromosomes Cancer; 2015 Dec; 54(12):796-808. PubMed ID: 26355645
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Identification of 6 gene markers for survival prediction in osteosarcoma cases based on multi-omics analysis.
    Li R; Wang G; Wu Z; Lu H; Li G; Sun Q; Cai M
    Exp Biol Med (Maywood); 2021 Jul; 246(13):1512-1523. PubMed ID: 33563042
    [TBL] [Abstract][Full Text] [Related]  

  • 29. MYC amplifications are common events in childhood osteosarcoma.
    De Noon S; Ijaz J; Coorens TH; Amary F; Ye H; Strobl A; Lyskjaer I; Flanagan AM; Behjati S
    J Pathol Clin Res; 2021 Sep; 7(5):425-431. PubMed ID: 33969640
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Genomic profiling of advanced-stage, metaplastic breast carcinoma by next-generation sequencing reveals frequent, targetable genomic abnormalities and potential new treatment options.
    Ross JS; Badve S; Wang K; Sheehan CE; Boguniewicz AB; Otto GA; Yelensky R; Lipson D; Ali S; Morosini D; Chliemlecki J; Elvin JA; Miller VA; Stephens PJ
    Arch Pathol Lab Med; 2015 May; 139(5):642-9. PubMed ID: 25927147
    [TBL] [Abstract][Full Text] [Related]  

  • 31. The Prognostic and Therapeutic Value of the Mutational Profile of Blood and Tumor Tissue in Head and Neck Squamous Cell Carcinoma.
    Wilson HL; D'Agostino RB; Meegalla N; Petro R; Commander S; Topaloglu U; Zhang W; Porosnicu M
    Oncologist; 2021 Feb; 26(2):e279-e289. PubMed ID: 33098199
    [TBL] [Abstract][Full Text] [Related]  

  • 32. The potential value of lncRNA-BC050642 in osteosarcoma origination and outcomes.
    Yang Y; Fei M; Zhou X; Li Y; Jin D
    Artif Cells Nanomed Biotechnol; 2019 Dec; 47(1):1859-1866. PubMed ID: 31397185
    [No Abstract]   [Full Text] [Related]  

  • 33. Subclonal Somatic Copy-Number Alterations Emerge and Dominate in Recurrent Osteosarcoma.
    Kinnaman MD; Zaccaria S; Makohon-Moore A; Arnold B; Levine MF; Gundem G; Arango Ossa JE; Glodzik D; Rodríguez-Sánchez MI; Bouvier N; Li S; Stockfisch E; Dunigan M; Cobbs C; Bhanot UK; You D; Mullen K; Melchor JP; Ortiz MV; O'Donohue TJ; Slotkin EK; Wexler LH; Dela Cruz FS; Hameed MR; Glade Bender JL; Tap WD; Meyers PA; Papaemmanuil E; Kung AL; Iacobuzio-Donahue CA
    Cancer Res; 2023 Nov; 83(22):3796-3812. PubMed ID: 37812025
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Hes4: A potential prognostic biomarker for newly diagnosed patients with high-grade osteosarcoma.
    McManus M; Kleinerman E; Yang Y; Livingston JA; Mortus J; Rivera R; Zweidler-McKay P; Schadler K
    Pediatr Blood Cancer; 2017 May; 64(5):. PubMed ID: 27786411
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Genomic Analysis Revealed Mutational Traits Associated with Clinical Outcomes in Osteosarcoma.
    Chi X; Ji T; Li J; Xu J; Tang X; Xie L; Meng F; Guo W
    Cancer Manag Res; 2021; 13():5101-5111. PubMed ID: 34234554
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Extracellular Vesicle RNA Sequencing Reveals Dramatic Transcriptomic Alterations Between Metastatic and Primary Osteosarcoma in a Liquid Biopsy Approach.
    Bao Q; Gong L; Wang J; Wen J; Shen Y; Zhang W
    Ann Surg Oncol; 2018 Sep; 25(9):2642-2651. PubMed ID: 29981024
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Comprehensive genomic profiling of head and neck squamous cell carcinoma reveals FGFR1 amplifications and tumour genomic alterations burden as prognostic biomarkers of survival.
    Dubot C; Bernard V; Sablin MP; Vacher S; Chemlali W; Schnitzler A; Pierron G; Ait Rais K; Bessoltane N; Jeannot E; Klijanienko J; Mariani O; Jouffroy T; Calugaru V; Hoffmann C; Lesnik M; Badois N; Berger F; Le Tourneau C; Kamal M; Bieche I
    Eur J Cancer; 2018 Mar; 91():47-55. PubMed ID: 29331751
    [TBL] [Abstract][Full Text] [Related]  

  • 38. The Clonal Evolution of Metastatic Osteosarcoma as Shaped by Cisplatin Treatment.
    Brady SW; Ma X; Bahrami A; Satas G; Wu G; Newman S; Rusch M; Putnam DK; Mulder HL; Yergeau DA; Edmonson MN; Easton J; Alexandrov LB; Chen X; Mardis ER; Wilson RK; Downing JR; Pappo AS; Raphael BJ; Dyer MA; Zhang J
    Mol Cancer Res; 2019 Apr; 17(4):895-906. PubMed ID: 30651371
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Genetic amplification of the vascular endothelial growth factor (VEGF) pathway genes, including VEGFA, in human osteosarcoma.
    Yang J; Yang D; Sun Y; Sun B; Wang G; Trent JC; Araujo DM; Chen K; Zhang W
    Cancer; 2011 Nov; 117(21):4925-38. PubMed ID: 21495021
    [TBL] [Abstract][Full Text] [Related]  

  • 40. A novel risk score model based on eight genes and a nomogram for predicting overall survival of patients with osteosarcoma.
    Wu G; Zhang M
    BMC Cancer; 2020 May; 20(1):456. PubMed ID: 32448271
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.